Convalescence plasma treatment of COVID-19 : results from a prematurely terminated randomized controlled open-label study in Southern Sweden
(2021) In BMC Research Notes 14. p.1-5- Abstract
OBJECTIVE: Convalescent plasma has been tried as therapy for various viral infections. Early observational studies of convalescent plasma treatment for hospitalized COVID-19 patients were promising, but randomized controlled studies were lacking at the time. The objective of this study was to investigate if convalescent plasma is beneficial to hospitalized patients with COVID-19.
RESULTS: Hospitalized patients with confirmed COVID-19 and an oxygen saturation below 94% were randomized 1:1 to receive convalescent plasma in addition to standard of care or standard of care only. The primary outcome was number of days of oxygen treatment to keep saturation above 93% within 28 days from inclusion. The study was prematurely terminated... (More)
OBJECTIVE: Convalescent plasma has been tried as therapy for various viral infections. Early observational studies of convalescent plasma treatment for hospitalized COVID-19 patients were promising, but randomized controlled studies were lacking at the time. The objective of this study was to investigate if convalescent plasma is beneficial to hospitalized patients with COVID-19.
RESULTS: Hospitalized patients with confirmed COVID-19 and an oxygen saturation below 94% were randomized 1:1 to receive convalescent plasma in addition to standard of care or standard of care only. The primary outcome was number of days of oxygen treatment to keep saturation above 93% within 28 days from inclusion. The study was prematurely terminated when thirty-one of 100 intended patients had been included. The median time of oxygen treatment among survivors was 11 days (IQR 6-15) for the convalescent plasma group and 7 days (IQR 5-9) for the standard of care group (p = 0.4, median difference -4). Two patients in the convalescent plasma group and three patients in the standard of care group died (p = 0.64, OR 0.49, 95% CI 0.08-2.79). Thus no significant differences were observed between the groups. Trial registration ClinicalTrials NCT04600440, retrospectively registered Oct 23, 2020.
(Less)
- author
- organization
- publishing date
- 2021
- type
- Contribution to journal
- publication status
- published
- subject
- in
- BMC Research Notes
- volume
- 14
- article number
- 440
- pages
- 1 - 5
- publisher
- BioMed Central (BMC)
- external identifiers
-
- pmid:34863304
- scopus:85120748357
- ISSN
- 1756-0500
- DOI
- 10.1186/s13104-021-05847-7
- language
- English
- LU publication?
- yes
- additional info
- © 2021. The Author(s).
- id
- 20148598-9f00-4307-b1c6-e7b7a174a3ce
- date added to LUP
- 2021-12-09 22:15:01
- date last changed
- 2024-09-13 10:37:11
@article{20148598-9f00-4307-b1c6-e7b7a174a3ce, abstract = {{<p>OBJECTIVE: Convalescent plasma has been tried as therapy for various viral infections. Early observational studies of convalescent plasma treatment for hospitalized COVID-19 patients were promising, but randomized controlled studies were lacking at the time. The objective of this study was to investigate if convalescent plasma is beneficial to hospitalized patients with COVID-19.</p><p>RESULTS: Hospitalized patients with confirmed COVID-19 and an oxygen saturation below 94% were randomized 1:1 to receive convalescent plasma in addition to standard of care or standard of care only. The primary outcome was number of days of oxygen treatment to keep saturation above 93% within 28 days from inclusion. The study was prematurely terminated when thirty-one of 100 intended patients had been included. The median time of oxygen treatment among survivors was 11 days (IQR 6-15) for the convalescent plasma group and 7 days (IQR 5-9) for the standard of care group (p = 0.4, median difference -4). Two patients in the convalescent plasma group and three patients in the standard of care group died (p = 0.64, OR 0.49, 95% CI 0.08-2.79). Thus no significant differences were observed between the groups. Trial registration ClinicalTrials NCT04600440, retrospectively registered Oct 23, 2020.</p>}}, author = {{Holm, Karin and Lundgren, Maria N and Kjeldsen-Kragh, Jens and Ljungquist, Oskar and Böttiger, Blenda and Wikén, Christian and Öberg, Jonas and Fernström, Nils and Rosendal, Ebba and Överby, Anna K and Wigren Byström, Julia and Forsell, Mattias and Landin-Olsson, Mona and Rasmussen, Magnus}}, issn = {{1756-0500}}, language = {{eng}}, pages = {{1--5}}, publisher = {{BioMed Central (BMC)}}, series = {{BMC Research Notes}}, title = {{Convalescence plasma treatment of COVID-19 : results from a prematurely terminated randomized controlled open-label study in Southern Sweden}}, url = {{http://dx.doi.org/10.1186/s13104-021-05847-7}}, doi = {{10.1186/s13104-021-05847-7}}, volume = {{14}}, year = {{2021}}, }